Document
IPR2024-00009, No. 2023 Exhibit - EX2023 Notice of Service for Defendants’ Supplemental Invalidity Contentions, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Nov...
Cite Document
IPR2024-00009, No. 2023 Exhibit - EX2023 Notice of Service for Defendants’ Supplemental Invalidity Contentions, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Nov 6, 2023 (P.T
+ More Snippets
Document
IPR2024-00009, No. 2020 Exhibit - EX2020 Novo Nordisk Production Letter, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Oct 17, 2023 REDACTED (P.T.A.B. Jan. 26...
Cite Document
IPR2024-00009, No. 2020 Exhibit - EX2020 Novo Nordisk Production Letter, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Oct 17, 2023 REDACTED (P.T.A.B. Jan. 26, 2024)
+ More Snippets
Document
IPR2024-00009, No. 2001 Exhibit - EX2001 Excerpt of Defendants’ Initial Invalidity Contentions Regarding US Patent Nos 8,129,343 8,536,122 8,114,833 8,920,383 9,775,953 9,457,154 and 10,335,462, In
Cite Document
IPR2024-00009, No. 2001 Exhibit - EX2001 Excerpt of Defendants’ Initial Invalidity Contentions Regarding US Patent Nos 8,129,343 8,536,122 8,114,833 8,920,383 9,775,953 9,457,154 and 10,335,462, In
+ More Snippets
Document
IPR2024-00009, No. 2018 Exhibit - EX2018 Excerpt of Defendants’ Supplemental Invalidity Contentions Regarding US Patent Nos 8,129,343 8,536,122 8,114,833 8,920,383 9,775,953 9,457,154 and 10,335,462
Cite Document
IPR2024-00009, No. 2018 Exhibit - EX2018 Excerpt of Defendants’ Supplemental Invalidity Contentions Regarding US Patent Nos 8,129,343 8,536,122 8,114,833 8,920,383 9,775,953 9,457,154 and 10,335,462
+ More Snippets
Document
IPR2024-00009, No. 2012 Exhibit - EX2012 Waiver of Service of Summons for Dr Reddy’s Laboratories, Inc, Novo Nordisk Inc v Dr Reddy’s Lab’ys Ltd, No 122 cv 00298 CFC, Dkt 6 D Del, Mar 4,...
Cite Document
IPR2024-00009, No. 2012 Exhibit - EX2012 Waiver of Service of Summons for Dr Reddy’s Laboratories, Inc, Novo Nordisk Inc v Dr Reddy’s Lab’ys Ltd, No 122 cv 00298 CFC, Dkt 6 D Del, Mar 4, 2022 (P.T.A
+ More Snippets
Document
IPR2024-00009, No. 2002 Exhibit - EX2002 Petition for Inter Partes Review, Mylan Pharms Inc v Novo Nordisk AS, IPR2023 00724, Pap1 Mar 16, 2023 (P.T.A.B. Jan. 26, 2024)
Cite Document
IPR2024-00009, No. 2002 Exhibit - EX2002 Petition for Inter Partes Review, Mylan Pharms Inc v Novo Nordisk AS, IPR2023 00724, Pap1 Mar 16, 2023 (P.T.A.B. Jan. 26, 2024)
+ More Snippets
Document
IPR2024-00009, No. 2022 Exhibit - EX2022 Notice of Service for Defendants’ Initial Invalidity Contentions, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Oct 20, 2022...
Cite Document
IPR2024-00009, No. 2022 Exhibit - EX2022 Notice of Service for Defendants’ Initial Invalidity Contentions, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Oct 20, 2022 (P.T.A.B
+ More Snippets
Document
IPR2024-00009, No. 2013 Exhibit - EX2013 Waiver of Service of Summons for Dr Reddy’s Laboratories Ltd, Novo Nordisk Inc v Dr Reddy’s Lab’ys Ltd, No 122 cv 00298 CFC, Dkt 7 D Del Mar 4, 2...
Cite Document
IPR2024-00009, No. 2013 Exhibit - EX2013 Waiver of Service of Summons for Dr Reddy’s Laboratories Ltd, Novo Nordisk Inc v Dr Reddy’s Lab’ys Ltd, No 122 cv 00298 CFC, Dkt 7 D Del Mar 4, 2022 (P.T.A.B
+ More Snippets
Document
IPR2024-00009, No. 2019 Exhibit - EX2019 Novo Nordisk Production Letter, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Oct 17, 2023 REDACTED (P.T.A.B. Jan. 26...
Cite Document
IPR2024-00009, No. 2019 Exhibit - EX2019 Novo Nordisk Production Letter, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Oct 17, 2023 REDACTED (P.T.A.B. Jan. 26, 2024)
+ More Snippets
Document
IPR2024-00009, No. 2015 Exhibit - EX2015 Excerpt of Novo Nordisk’s Initial Responses to Defendants’ Initial Invalidity Contentions Regarding US Patent Nos 8,129,343 8,536,122 8,114,833 8...
Cite Document
IPR2024-00009, No. 2015 Exhibit - EX2015 Excerpt of Novo Nordisk’s Initial Responses to Defendants’ Initial Invalidity Contentions Regarding US Patent Nos 8,129,343 8,536,122 8,114,833 8,920,383 9,7
+ More Snippets
Document
IPR2024-00009, No. 1081 Exhibit - Ozempic prescribing information Oct 2022 (P.T.A.B. Oct. 20, 2023)
Cite Document
IPR2024-00009, No. 1081 Exhibit - Ozempic prescribing information Oct 2022 (P.T.A.B. Oct. 20, 2023)
+ More Snippets
Document
IPR2024-00009, No. 1042 Exhibit - WO 9111457 (P.T.A.B. Oct. 20, 2023)
Cite Document
IPR2024-00009, No. 1042 Exhibit - WO 9111457 (P.T.A.B. Oct. 20, 2023)
+ More Snippets
Document
IPR2024-00009, No. 1036 Exhibit - Mojsov, Insulinotropin,79 J CLINICAL INVESTIGATION 616 1987 (P.T.A.B. Oct. 20, 2023)
Cite Document
IPR2024-00009, No. 1036 Exhibit - Mojsov, Insulinotropin,79 J CLINICAL INVESTIGATION 616 1987 (P.T.A.B. Oct. 20, 2023)
+ More Snippets
Document
IPR2024-00009, No. 1072 Exhibit - US Patent No 5,164,366 (P.T.A.B. Oct. 20, 2023)
Cite Document
IPR2024-00009, No. 1072 Exhibit - US Patent No 5,164,366 (P.T.A.B. Oct. 20, 2023)
+ More Snippets
Document
IPR2024-00009, No. 1065 Exhibit - Tasneem, The Database for Aggregate Analysis,73 PLOS ONE 12012 (P.T.A.B. Oct. 20, 2023)
Cite Document
IPR2024-00009, No. 1065 Exhibit - Tasneem, The Database for Aggregate Analysis,73 PLOS ONE 12012 (P.T.A.B. Oct. 20, 2023)
+ More Snippets